Next-generation CRISPR tools and therapies improved by modified RNA guides
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), a gene-editing tool, is a promising way to treat diseases by removing, adding, or altering sections of deoxyribonucleic acid (DNA) sequences. It is currently the most straightforward, most flexible, and accurate method of gene manipulation.
A new type of gene-editing tool, CRISPR-Cas13, has shown promise in RNA targeting. Previous studies have shown the tool as a potential treatment method for viral diseases, including coronavirus disease (COVID-19).
Researchers at the lab of Neville Sanjana at New York University (NYU) and the New York Genome Center (NYGC) have developed chemically modified guide RNAs for a CRISPR system that targets RNA instead of DNA.
Gene Editing: This Healthcare Breakthrough Gives Me Chills
investorplace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investorplace.com Daily Mail and Mail on Sunday newspapers.
Canadian ethicists question plan to end limits on culturing human embryos
cruxnow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cruxnow.com Daily Mail and Mail on Sunday newspapers.
• U.S. Patent Application No.14/704,551 – claims 2 and 4-18
• U.S. Patent Application No.15/330,876 – claims 1, 16-21, and 30-40,
against only one pending application for Toolgen:
• U.S. Patent Application Publication No. US20150344912 (Application No. 14/685,510) - claims 66-68, 70-74, 83, 85-88, and 90-94.
None of the claims of any of the patents or applications of either party were designated as not corresponding to the Count.
The count of the interference is set forth in the alternative, either as claim 18 of the Broad s U.S. Patent No. 8,697,359 (dependent on claim 15), which taken together recites the following invention:
An engineered, programmable, non-naturally occurring Type II CRISPR-Cas system comprising a Cas9 protein and at least one guide RNA that targets and hybridizes to a target sequence of a DNA molecule in a eukaryotic cell, wherein the DNA molecule encodes and the eukaryotic cell expresses at least one gene product and the Cas9 protein cleaves the
Captain America in real life: China, France develop biologically-enhanced super soldiers
The soldiers will allow for location tracking, connectivity with other troops, and drugs that will help keep soldiers awake for long periods.
December 23, 2020 10:59 GMT
Fans of Captain America may be able to see a real-life version soon as China and France are developing biologically-enhanced super soldiers.
China has already started creating super soldiers and France has joined in on the bandwagon. A top intelligence official from the US revealed that in China, there were already members of China s People s Liberation Army who were subjected to human testing for their Captain America-like super soldiers. In France, its army got the go-ahead to create bionic soldiers with prosthetics and treatment which would make them faster and stronger.